ATE430563T1 - Cyano-substituierte oleanolsäure als inhibitor der no-produktion - Google Patents

Cyano-substituierte oleanolsäure als inhibitor der no-produktion

Info

Publication number
ATE430563T1
ATE430563T1 AT99928731T AT99928731T ATE430563T1 AT E430563 T1 ATE430563 T1 AT E430563T1 AT 99928731 T AT99928731 T AT 99928731T AT 99928731 T AT99928731 T AT 99928731T AT E430563 T1 ATE430563 T1 AT E430563T1
Authority
AT
Austria
Prior art keywords
cyano
inhibitor
production
substituted
moiety selected
Prior art date
Application number
AT99928731T
Other languages
English (en)
Inventor
Gordon Gribble
Tadashi Honda
Michael Sporn
Nanjoo Suh
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22221055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE430563(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dartmouth College filed Critical Dartmouth College
Application granted granted Critical
Publication of ATE430563T1 publication Critical patent/ATE430563T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99928731T 1998-06-19 1999-06-18 Cyano-substituierte oleanolsäure als inhibitor der no-produktion ATE430563T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9005398P 1998-06-19 1998-06-19
US09/335,003 US6326507B1 (en) 1998-06-19 1999-06-17 Therapeutic compounds and methods of use
PCT/US1999/013635 WO1999065478A1 (en) 1998-06-19 1999-06-18 Therapeutic compositions and methods of use

Publications (1)

Publication Number Publication Date
ATE430563T1 true ATE430563T1 (de) 2009-05-15

Family

ID=22221055

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928731T ATE430563T1 (de) 1998-06-19 1999-06-18 Cyano-substituierte oleanolsäure als inhibitor der no-produktion

Country Status (10)

Country Link
US (7) US6326507B1 (de)
EP (2) EP1089724B1 (de)
JP (3) JP4541548B2 (de)
AT (1) ATE430563T1 (de)
CA (1) CA2335505C (de)
CY (1) CY1109256T1 (de)
DK (1) DK1089724T3 (de)
ES (1) ES2324966T3 (de)
PT (1) PT1089724E (de)
WO (1) WO1999065478A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20040072138A1 (en) * 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
WO2001054688A1 (en) * 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
EP1395255A4 (de) * 2000-11-28 2007-09-12 Univ Texas Cddo-verbindungen und kombinationstherapien dafür
US6777004B1 (en) * 2001-03-30 2004-08-17 Council Of Scientific & Industrial Research Composition containing novel compound corniculatonin having antifungi properties and a process for preparing the same
KR100464063B1 (ko) * 2001-11-21 2005-01-06 한국생명공학연구원 세포사멸 유도작용을 갖는 트리테르펜 화합물
EP1465615B1 (de) * 2002-01-15 2012-08-01 Trustees of Dartmouth College Trizyklische bisenon-derivate und verfahren zu ihrer verwendung
MXPA04010927A (es) * 2002-05-02 2006-01-30 Univ Washington Metodos y composiciones para el tratamiento de enfermedades y trastornos inflamatorios/autoinmunes producidos por linfocitos t en sujetos que padecen una deficiencia en la regulacion de glucocorticoides.
CA2485565A1 (en) * 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
CN100518742C (zh) * 2003-10-10 2009-07-29 Sk化学株式会社 有效改善脑功能的三萜化合物
US20050208151A1 (en) * 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
US7551346B2 (en) * 2003-11-05 2009-06-23 E Ink Corporation Electro-optic displays, and materials for use therein
MXPA06007378A (es) * 2003-12-23 2007-01-26 Musc Found For Res Dev Metodos y composiciones para la prevencion y tratamiento de enfermedades o condiciones inflamatorias.
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
WO2006006152A2 (en) * 2004-07-08 2006-01-19 Ramot At Tel-Aviv University Ltd Treatment of disorders and diseases of the colon
JP5197355B2 (ja) * 2005-03-08 2013-05-15 三井農林株式会社 ポリフェノールとコキシブの組み合わせおよび方法
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
US8299046B2 (en) * 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
WO2008064133A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
US20080227846A1 (en) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
WO2009023845A2 (en) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
WO2009058849A1 (en) * 2007-10-29 2009-05-07 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
CN104739841B (zh) 2008-01-11 2018-06-01 里亚塔医药公司 合成三萜类化合物及用以治病之方法
ES2326065B1 (es) * 2008-03-28 2010-07-08 Consejo Superior De Investigaciones Cientificas (Csic) Utilizacion de un triterpeno pentaciclico para la preparacion de una composicion farmaceutica destinada al tratamiento de la esclerosis multiple.
KR101665042B1 (ko) * 2008-04-18 2016-10-11 리타 파마슈티컬스 잉크. 소염성 골격군을 포함하는 화합물 및 사용 방법
EP2279197B1 (de) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidationsmittel als entzündungsmodulierende substanz: im c-ring gesättigte oleanolsäurederivate
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
US8071632B2 (en) * 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
WO2010011782A1 (en) * 2008-07-22 2010-01-28 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
KR101483203B1 (ko) 2009-02-13 2015-01-15 리아타 파마슈티컬즈, 아이엔씨. 무정형 ｃｄｄｏ-ｍｅ를 포함하는, 지연 방출형 경구 투여 조성물
EP2424598B1 (de) * 2009-04-30 2013-12-11 Sanofi-Aventis Deutschland GmbH Vorrichtung zur Entfernung einer Nadel und Verfahren zur Entfernung einer Nadel
AU2011240690C1 (en) 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
KR101220782B1 (ko) 2010-09-14 2013-01-09 제주대학교 산학협력단 신규 트리테르페노이드 및 이의 용도
JP5857068B2 (ja) 2010-12-17 2016-02-10 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーターとしてのピラゾリルおよびピリミジニル三環式エノン
TR201909788T4 (tr) 2011-03-11 2019-07-22 Reata Pharmaceuticals Inc C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
DK2841445T3 (en) 2012-04-27 2017-09-11 Reata Pharmaceuticals Inc 2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONMETHYL, POLYMORPHE FORMS THEREOF AND PROCEDURES FOR USING IT
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US8791067B2 (en) 2012-07-24 2014-07-29 Morehouse School Of Medicine Method for treating malaria
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
DK2892911T3 (en) * 2012-09-10 2017-10-23 Reata Pharmaceuticals Inc C17 heteroaryl derivatives of oleanolic acid and methods of use thereof
MX2015003021A (es) * 2012-09-10 2015-11-09 Abbvie Inc Derivados de acido glicirretinico y metodos de uso de los mismos.
BR112015005168A2 (pt) 2012-09-10 2017-08-15 Reata Pharmaceuticals Inc Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
CN102887936A (zh) * 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
US9796752B2 (en) 2013-03-19 2017-10-24 Daiichi Sankyo Company, Limited Terpenoid derivatives
AR096046A1 (es) 2013-04-24 2015-12-02 Abbvie Inc Derivados de 2,2-difluoropropanamida de metil bardoxolona, formas polimórficas y métodos de uso
US9290455B2 (en) 2014-02-11 2016-03-22 Trustees Of Dartmouth College CDDO-Me amino acid conjugates and methods of use
WO2016033132A1 (en) 2014-08-26 2016-03-03 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
US10189791B2 (en) 2014-08-26 2019-01-29 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
US10208082B2 (en) 2014-09-10 2019-02-19 Daiichi Sankyo Company, Limited Sustained-release pharmaceutical composition for treatment and prevention of eye disease
NZ734292A (en) 2015-02-12 2022-09-30 Reata Pharmaceuticals Inc Imidazolyl tricyclic enones as antioxidant inflammation modulators
ES2865163T3 (es) 2015-09-23 2021-10-15 Reata Pharmaceuticals Inc Derivados de ácido oleanólico modificado en C4 para la inhibición de il-17 y otros usos
MA46749A (fr) 2016-11-08 2019-09-18 Reata Pharmaceuticals Inc Méthodes de traitement du syndrome d'alport à l'aide d'un méthyle de bardoxolone ou d'analogues de ce dernier
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
CN110536685A (zh) * 2016-12-23 2019-12-03 昆士兰大学 Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病
WO2019014412A1 (en) 2017-07-13 2019-01-17 Pliva Hrvatska D.O.O. NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
JP7498122B2 (ja) 2018-06-15 2024-06-11 リアタ ファーマシューティカルズ インコーポレイテッド ＩＬ－１７およびＲＯＲγの阻害用のピラゾール化合物およびイミダゾール化合物
EP3810141A1 (de) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteinabhängige inverse agonisten von kernrezeptoren-ror-gamma/ror-gamma-t und verfahren zur behandlung von erkrankungen oder störungen damit
KR20210096162A (ko) 2018-11-27 2021-08-04 쿄와 기린 가부시키가이샤 의약 조성물
US12344631B2 (en) 2019-07-19 2025-07-01 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
TW202340204A (zh) 2022-01-07 2023-10-16 日商中外製藥股份有限公司 具有Nrf2活化作用的含氮雜環化合物
WO2025029691A1 (en) * 2023-07-28 2025-02-06 Reata Pharmaceuticals Holdings, LLC Methods for producing triterpenoid derivatives

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
NZ191586A (en) * 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0184365B1 (de) 1984-12-04 1993-08-04 Eli Lilly And Company Tumorbehandlung bei Säugetieren
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
PT86377B (pt) 1986-12-24 1990-11-20 Lilly Co Eli Processo para a preparacao de conjugados de imunoglobulinas com um difluoronucleosideo acilado
IL89258A0 (en) 1988-02-16 1989-09-10 Lilly Co Eli 2',3'-dideoxy-2',2'-difluoro-nucleosides
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
AU7558491A (en) 1990-04-04 1991-10-30 Nycomed Imaging As Nucleoside derivatives
ES2115665T3 (es) 1991-01-29 1998-07-01 Shionogi & Co Derivado de triterpeno.
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
US5401838A (en) 1992-06-22 1995-03-28 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
UA41261C2 (uk) 1992-06-22 2001-09-17 Елі Ліллі Енд Компані Спосіб одержання збагачених бета-аномером нуклеозидів
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
YU43193A (sh) 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
DE4308042C2 (de) 1993-03-13 2000-10-12 Alstom Energy Syst Gmbh Wälzmühle
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5972703A (en) 1994-08-12 1999-10-26 The Regents Of The University Of Michigan Bone precursor cells: compositions and methods
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
ATE249842T1 (de) 1996-07-03 2003-10-15 Upjohn Co Zielgerichte arzneimittel abgabe für zulphonamide-derivate
ATE236188T1 (de) 1997-01-24 2003-04-15 Conpharma As Gemcitabin-derivate
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6485756B1 (en) * 1999-04-06 2002-11-26 Collaborative Technologies, Inc. Stable, homogeneous natural product extracts containing polar and apolar fractions
CA2372962C (en) 1999-05-14 2008-04-08 Nereus Pharmaceuticals, Inc. Novel interleukin-1 and tumor necrosis factor-.alpha. modulators, syntheses of said modulators and methods of using said modulators
JP3737968B2 (ja) 1999-06-25 2006-01-25 ロシュ ダイアグノスティックス コーポレーション 酵素阻害イムノアッセイ
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
EP1395255A4 (de) 2000-11-28 2007-09-12 Univ Texas Cddo-verbindungen und kombinationstherapien dafür
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
JP2005514359A (ja) 2001-11-23 2005-05-19 中外製薬株式会社 腫瘍を標的とする酵素の同定法
EP1465615B1 (de) 2002-01-15 2012-08-01 Trustees of Dartmouth College Trizyklische bisenon-derivate und verfahren zu ihrer verwendung
CA2485565A1 (en) 2002-05-13 2004-08-05 Trustees Of Dartmouth College Inhibitors and methods of use thereof
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
AU2005282437B2 (en) 2004-09-07 2013-01-10 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
US20050208151A1 (en) 2003-10-30 2005-09-22 Entelos, Inc. Treatment of rheumatoid arthritis with FLIP antagonists
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication
EP1959969A2 (de) 2005-07-01 2008-08-27 The Johns Hopkins University Zusammensetzungen und verfahren zur behandlung oder prävention von erkrankungen im zusammenhang mit oxidativem stress
DE102005041613A1 (de) 2005-09-01 2007-03-08 Ergonex Pharma Gmbh Pharmazeutische Zusammensetzungen zur Behandlung von Karzinoid-Syndrom
US8067357B2 (en) 2005-12-12 2011-11-29 Mosamedix B.V. Annexin derivatives suitable for pretargeting in therapy and diagnosis
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
WO2008064133A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
JP2008247898A (ja) 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008136838A1 (en) * 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009023845A2 (en) 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
CN104739841B (zh) 2008-01-11 2018-06-01 里亚塔医药公司 合成三萜类化合物及用以治病之方法
EP2279197B1 (de) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidationsmittel als entzündungsmodulierende substanz: im c-ring gesättigte oleanolsäurederivate
KR101665042B1 (ko) 2008-04-18 2016-10-11 리타 파마슈티컬스 잉크. 소염성 골격군을 포함하는 화합물 및 사용 방법
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
WO2010011782A1 (en) 2008-07-22 2010-01-28 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
KR101483203B1 (ko) 2009-02-13 2015-01-15 리아타 파마슈티컬즈, 아이엔씨. 무정형 ｃｄｄｏ-ｍｅ를 포함하는, 지연 방출형 경구 투여 조성물
AU2011240690C1 (en) 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
TR201909788T4 (tr) 2011-03-11 2019-07-22 Reata Pharmaceuticals Inc C4-monometil triterpenoid türevleri ve bunların kullanım yöntemleri.

Also Published As

Publication number Publication date
US20130237721A1 (en) 2013-09-12
US8586775B2 (en) 2013-11-19
WO1999065478A1 (en) 1999-12-23
US20030236303A1 (en) 2003-12-25
US20080234368A9 (en) 2008-09-25
CA2335505C (en) 2010-06-15
US6326507B1 (en) 2001-12-04
CY1109256T1 (el) 2014-07-02
US7288568B2 (en) 2007-10-30
ES2324966T3 (es) 2009-08-20
US20140275618A1 (en) 2014-09-18
EP1089724A1 (de) 2001-04-11
JP2002530272A (ja) 2002-09-17
PT1089724E (pt) 2009-07-20
US9278913B2 (en) 2016-03-08
EP1089724B1 (de) 2009-05-06
JP5210971B2 (ja) 2013-06-12
JP2009242409A (ja) 2009-10-22
DK1089724T3 (da) 2009-07-27
US7863327B2 (en) 2011-01-04
US20020042535A1 (en) 2002-04-11
CA2335505A1 (en) 1999-12-23
US20050288363A1 (en) 2005-12-29
EP2062577A1 (de) 2009-05-27
JP2012144574A (ja) 2012-08-02
US6552075B2 (en) 2003-04-22
JP4541548B2 (ja) 2010-09-08
US20080220057A1 (en) 2008-09-11
US8034955B2 (en) 2011-10-11
EP1089724A4 (de) 2004-06-09

Similar Documents

Publication Publication Date Title
ATE430563T1 (de) Cyano-substituierte oleanolsäure als inhibitor der no-produktion
DK0931788T3 (da) Metalloproteasehæmmere
BR0010242A (pt) Composições quìmicas que atraem artrópodes
SE0100902D0 (sv) Compounds
DK0906907T3 (da) Forbindelser, der potenserer retinoid
PT1076663E (pt) Derivados funcionalizados de alquilo e alcenilo de cadeia lateral de glicinamidas como inibidores de farnesil transferase
ATE271045T1 (de) Sauerstoffhaltige heterocyclische verbindungen
IS5497A (is) Bífenýlamidínafleiður
ATE239741T1 (de) Derivate der phosphonsäure zur inhibierung von carboxypeptidase b
DK0753511T3 (da) 4-indol-1-ylsmørsyrederivater, deres fremstilling og deres anvendelse som inhibitorer af alfa 1-adrenerge receptorer og testosteron-5alfa-reduktaser
IN190321B (de)
DE69915514D1 (de) Prenyltransferase-inhibitoren
EA200001036A1 (ru) Способы ингибирования mrp1
EP1403268A4 (de) Fluoreszente sonden für zink
BR0001627A (pt) Composições para controle de baratas
DK0963998T3 (da) Azasteroidforbindelse til behandling eller prævention af prostatacancer
BR9913012A (pt) Processo para preparar um composto, e, composto.
BR9912208A (pt) Compostos orgânicos
NO20000054D0 (no) Polyhydroksyalkylpyrazinderivater, deres fremstilling og medisiner inneholdende forbindelsene
DK1424329T3 (da) Fremgangsmåde til fremstillingen af 4-(imidazol-1-yl)benzensulfonamid
TH26544A (th) อนุพันธ์กรด -4 - อัลคิลไทโอ -ไพรมิดิน -5 - อิล อาซีติก
ATE420855T1 (de) 2-substituierte vitamin-d-derivate
ECSP982576A (es) Derivados de epotilona

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1089724

Country of ref document: EP